drugset / Trial / NCT00475852

A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure

NCT00475852 ↗

Phase 3 Completed 7141 enrolled Scios, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to find out if nesiritide (a human B-type natriuretic peptide/hBNP) as compared to placebo, plus the usual treatment for acute decompensated heart failure, helps to improve breathing difficulties, reduce heart failure readmissions to hospitals, and helps patients live longer.

Timeline

Start
2007-05
Primary completion
2011-03
Completion
2011-03

Outcome

Missed primary endpoint

registry Nesiritide vs Placebo; p = 0.313; Risk Difference (RD) -0.7 (95% CI -2.1 to 0.7); Cochran-Mantel-Haenszel NCT00475852 ↗

paper the prespecified level for significance (P≤0.005 for both assessments or P≤0.0025 for either) was not met. PMID 21732835 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Nesiritide Protein / enzyme biologic 0.01 ug/kg Intravenous

Indications